In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimera readies for Iluvien resubmission, partner pSivida says

This article was originally published in Scrip

Executive Summary

With approvals racking up in Europe for Iluvien (fluocinolone acetonide intravitreal insert) – most recently in Germany, Austria, France, Portugal and the UK – pSivida was eager to tell investors that its partner Alimera Sciences is ready to resubmit its application to FDA for marketing in the US, where the company has struggled to make it to the finish line with the drug as a treatment for diabetic macular edema (DME) (scripintelligence, 27 July 2012, 20 July 2012, 7 June 2012, 8 May 2012, 29 February 2012).

You may also be interested in...



Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Allergan's Price Reform Pledge: Will Others Follow?

Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.

Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?

Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel